General Proximity pioneers next-generation medicines by controlling biological processes through proximity. Redefining the future of medicine for all humankind. Backed by Y Combinator and Felicis.
About the role
We are seeking an exceptional computational chemist to support our computational chemistry, cheminformatics, and molecular design efforts. This role will help drive small-molecule drug discovery programs by providing practical modeling support, applying modern computational workflows, and using the cheminformatics and AI-enabled tools that empower medicinal chemists and project teams.
What they're looking for
- PhD in Computational Chemistry, Medicinal Chemistry, Chemical Physics, Biophysics, Cheminformatics, Physical Organic Chemistry, or a related discipline
- A minimum of 3 years of relevant experience in pharma, biotech, or a drug discovery-focused research environment
- Track record of using computational chemistry to impact small-molecule drug discovery programs, ideally through hit-to-lead or lead optimization
- Hands-on expertise in structure-based drug design, ligand-based design, docking, molecular dynamics, virtual screening, QSAR, FEP/free-energy methods, pharmacophore modeling, and multi-parameter optimization
- Strong working knowledge of medicinal chemistry principles, SAR interpretation, physicochemical property optimization, ADME/PK concepts, and developability considerations
- Practical experience with cheminformatics platforms, chemical databases, chemical data curation, compound registration systems, and project-facing visualization tools
More about this role
General Proximity is a seed-stage startup developing the next generation of induced proximity medicines (IPMs). Our OmniTAC drug discovery engine furnishes molecules that co-opt existing cellular machinery to overcome therapeutic challenges, which have remained unapproachable to other modalities for decades.
We are seeking a first-rate computational chemist to help us pioneer this uncharted frontier of drug discovery.
A long-standing challenge in drug discovery is the development of molecules capable of modulating difficult or "undruggable" targets. Disease-causing proteins can be dysfunctional in many different ways, but our armamentarium for fixing them is quite limited. The most common mechanism of action for FDA-approved drugs is inhibition [1] , but there are many other possible perturbation types whose potential remains unrealized.
General Proximity is a seed-stage drug discovery company developing a novel platform technology to solve this problem. We make bifunctional drugs that induce the modification of drug targets by existing cellular machinery (rather than through direct modulation by the drug, the classical approach).
Historically, the development of technologies that...
Browse similar: Startup jobs · San Francisco Bay Area